Skip to main content
Markets
/
AUROPHARMA · NSE
Market closedNSE | BSE
Loading live market indices
AU
NSE · Equity shares · Major Drugs

Aurobindo Pharma AUROPHARMA

NSE:INR 1,588.9Recorded price
BSE:INR 1,589.5Recorded price
Not available · Not available
Advanced chart
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceStale · last-known data
Company fundamentalsStale · last-known data
Research sections8 of 9 availableMissing source values remain unavailable, never zero-filled.
Snapshot

Price and key statistics

Reported and computed values remain separate; missing values are not converted to zero.

Previous closeData unavailable
Day rangeINR 1,585 — INR 1,634.3
52-week rangeINR 1,017 — INR 1,636
VolumeNot available
Market cap91,456.32
P/E21.62
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)33,653.08
Net Income (INR Cr)3,504.75
Rev Growth (5 Year %)6.32
EPS Growth (5 Year %)-7.9
P/E Ratio21.62
Book Value561.46
EPS61.98
Price/BV2.83Computed

Research path: Interpret Aurobindo Pharma's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.

AI and Advanced

AI analysis and Advanced tools for AUROPHARMA

Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.

AI analysisReview the complete evidence-led AI research workflow.Generate reportCreate a versioned report with entitlement and credit checks.Open AI ChatContinue a grounded conversation with the instrument in context.Advanced modulesOpen role- and entitlement-controlled portfolio and trading tools.
Validated OHLC

Interactive price chart

Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.

Open full workspace
Interactive price chartInteractive chart loads when this section is visible.
Auditable calculations

Daily technical summary

Calculated from validated daily candles. Descriptive research only.

Calculating technicals…
Intelligence: activity, structure and reported deals

Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.

Company derivatives · NSE

AUROPHARMA futures & options

Expiry structure, futures, option chains and contract research.

Snapshot · timestamp unavailable
No observations

No matching contracts have verified observations for this filter.

DIRECTION · ACTIVITY · DISCLOSURES

AUROPHARMA Intelligence

Stored price, volume, causal structure and reported deals for this stock.

Market map
Checking research access…

Volume and pressure are activity estimates, not net money inflow. Futures and options retain their separate observations above.

Company reporting

Financial statements

IND AS · INR crore

Metric202620252024
Total Liabilities Shareholders' Equity58,502.1549,784.9745,071.51
Accumulated Depreciation Total-7,904.59-6,538.47-6,372.69
Cash Equivalents5,376.682,919.572,110.91
Other Liabilities Total1,178.64351.57277.59
Accrued Expenses503.71246.26346.26
Long Term Debt802.751,561.652,134.9
Common Stock Total58.0858.0858.59
Other Equity Total3,799.051,838.521,517.99
Other Current Assets Total70.2243.13445.24
Total Assets58,502.1549,784.9745,071.51
Current Portof LT Debt/Capital Leases897.511,152.29182.08
Additional Paid-In Capital75.1175.11417.89
Cash1,814.722,649.381,282.57
Total Equity37,890.9732,653.3229,842.8
Long Term Investments303.88251.7321.65
Retained Earnings(Accumulated Deficit)33,958.7330,681.6127,848.33
Total Common Shares Outstanding58.0858.0858.59
Property/Plant/Equipment Total-Gross25,243.3521,993.920,657.59
Tangible Book Valueper Share Common Eq561.46489.23439.74
Goodwill Net800.15618.02595.15
Total Liabilities20,611.1817,131.6515,228.71
Total Debt8,072.848,262.876,647.63
Short Term Investments3,393.522,632.332,932.88
Cashand Short Term Investments10,584.928,201.286,326.36
Total Receivables Net10,000.678,374.337,625.8
Notes Payable/Short Term Debt6,079.645,309.724,078.12
Deferred Income Tax306303.27356.56
Accounts Receivable-Trade Net7,120.695,873.955,036.43
Property/Plant/Equipment Total-Net17,338.7615,455.4314,284.9
Minority Interest-8.16-6.398
Total Current Liabilities18,039.0114,682.3412,199.13
Total Inventory12,052.9410,543.729,808.23
Accounts Payable5,567.274,188.854,454.16
Other Currentliabilities Total4,990.883,785.223,138.51
Total Long Term Debt1,095.691,800.862,387.43
Intangibles Net4,481.233,620.73,481.46
Other Long Term Assets Total1,656.921,468.331,366.35
Note Receivable-Long Term1,212.461,208.33816.37
Total Current Assets32,708.7527,162.4624,205.63
Capital Lease Obligations292.94239.21252.53
Fundamentals

Valuation and ratios

Valuation

PEG Ratio1.19

Price to Sale Ratio2.72

Growth

Debt 5Yr CAGR %8.41

Margins

Operating Margin 12m14.86

Operating Margin 5y Avg13.8

Net Profit Margin 12m10.41

Net Profit Margin 5y10.32

Yield

Dividend Yield %0.25

Risk and consensus

Source-qualified signals

Risk metrics

Overall RiskBalanced risk

Board Risk27.4

Analyst consensus

ConsensusBuy

Consensus score2.22

Analyst opinions27

Strong Sell count1

Sell count3

Hold count5

Buy count10

Strong Buy count8

Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.
Industry context

Peer comparison

Only peers present in the company profile payload are displayed.

CompanyPriceMarket capP/EResearch
Neuland LaboratoriesINR 21,64527,583.3664.28—
PfizerINR 4,90022,334.8527.53—
Unichem LaboratoriesINR 493.053,476.6154.27—
Jagsonpal PharmaceuticalsINR 236.751,560.8834.27—
Themis MedicareINR 112.651,035.27632.19—
Shareholding

Ownership

Promoter
51.88%
FII
16.38%
MF
16.71%
Other
15.03%
Corporate actions

Events

  1. annual General MeetingAGM
  2. board MeetingsQuarterly Results
  3. board MeetingsAudited Results
  4. annual General MeetingBuy Back of Shares
  5. board MeetingsBuy Back of Shares
  6. annual General MeetingPOM
  7. board MeetingsQuarterly Results
  8. board MeetingsQuarterly Results
  9. annual General MeetingAGM
  10. dividendRs.4.0000 per share(400%)Interim Dividend
  11. board MeetingsQuarterly Results & Interim Dividend
  12. board MeetingsAudited Results
  13. annual General MeetingPOM
  14. board MeetingsQuarterly Results
  15. board MeetingsQuarterly Results
  16. annual General MeetingAGM
  17. board MeetingsQuarterly Results
  18. annual General MeetingBuy Back of Shares
  19. board MeetingsTo consider buyback for equity shares
  20. board MeetingsAudited Results
Rusaka Markets Community

Discussion and sentiment for Aurobindo Pharma

Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.

Rusaka Markets Community

Community discussion loads as you approach this section.

Company profile

Business information

What the company does

Aurobindo Pharma Limited is an India-based pharmaceutical company. The Company is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, branded pharmaceuticals, generic pharmaceuticals, and related services. Its key therapeutic segments include Central nervous systems (CNS), Antiretrovirals (ARVs), Cardiovascular (CVS), SSP - Orals and Sterile, Anti-infectives, Anti-diabetics and Cephalosporins - Orals. It is engaged in developing a range of oncology, non-oncology prescription formulation, and hormonal products. It is developing topical as well as transdermal products in the dermatology therapeutic segment. It is marketing its products globally in approximately 150 countries. Its subsidiaries include APL Healthcare Limited, Auronext Pharma Private Limited, Auro Peptides Limited, APL Pharma Thai Limited, Auro Pharma Inc, Aurobindo Pharma (Malta) Limited, APL Swift Services (Malta) Limited, Aurobindo Pharma Industria Farmaceutica Ltd, and others.

Company facts

Industry
Major Drugs
Sector
Major Drugs
NSE Code
AUROPHARMA
BSE Code
524804
Questions

Stock FAQ

What is the symbol and ISIN of Aurobindo Pharma?

Aurobindo Pharma has the symbol AUROPHARMA and ISIN - INE406A01037.

What is the latest recorded price of Aurobindo Pharma?

The latest available recorded price of Aurobindo Pharma is INR 1,588.90 as of 2026-08-06T20:45:47.571Z. This is a source-stamped snapshot, not a live quote.

What are the year high and year low of Aurobindo Pharma?

Year high: INR 1,636.00. Year low: INR 1,017.00.

What is the market capitalization of Aurobindo Pharma?

Market capitalization: INR 91,456.32 crore.

What is the P/E ratio of Aurobindo Pharma?

P/E ratio: 21.62.

What is the dividend yield of Aurobindo Pharma?

Dividend yield: 0.25%.

How is the financial performance of Aurobindo Pharma based on revenue, net income, and EPS?

Revenue: INR 33,653.08 crore. Net income: INR 3,504.75 crore. EPS: INR 61.11.

What is the book value of Aurobindo Pharma?

Book value: INR 561.46.

What are the price-to-book and price-to-sales ratios of Aurobindo Pharma?

Price-to-book ratio: 2.83. Price-to-sales ratio: 2.72.

Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.